nach oben

International Journal of Clinical Oncology

Erschienen in:

13.11.2019 | Original Article

The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease

verfasst von: Naoki Nishiyama, Takayuki Honda, Manabu Sema, Tatsuo Kawahara, Yasuto Jin, Ichiro Natsume, Tomoshige Chiaki, Takaaki Yamashita, Yoshikazu Tsukada, Reiko Taki, Yoshihiro Miyashita, Kazuhito Saito, Tomoya Tateishi, Hiroyuki Sakashita, Yasunari Miyazaki

Erschienen in: International Journal of Clinical Oncology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Acute exacerbation (AE) of interstitial lung disease (ILD) is a fatal adverse event in the treatment of lung cancer patients with ILD. The value of pre-treatment radiological findings obtained by high-resolution computed tomography for the detection of anticancer treatment-related AE of ILD has not been established.

Methods

Two medical record-based retrospective studies were performed. The chemotherapy cohort included 105 lung cancer patients with ILD who received chemotherapy at Tokyo Medical and Dental University between October 2008 and December 2017. The immune checkpoint inhibitor (ICI) cohort included 48 advanced non-small cell lung cancer patients with ILD treated with ICIs at nine institutions between January 2016 and September 2018. Variables were compared between AE-positive and -negative groups. Candidate variables were analyzed by multivariate logistic regression. A P value < 0.05 was considered statistically significant.

Results

Anticancer treatment-related AE of ILD occurred in 12 patients (11.4%) in the chemotherapy cohort and seven patients (14.5%) in the ICI cohort. In the multivariate logistic regression analysis, ground-glass attenuation (GGA) score was the only factor significantly associated with the development of AE of ILD in both cohorts (P = 0.037 and 0.01 in the chemotherapy and ICI cohorts, respectively).

Conclusion

Evaluation of GGA may help predict anticancer treatment-related AE of ILD.

Nur mit Berechtigung zugänglich

Raghu G, Nyberg F, Morgan G (2004) The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer 91:S3. https://doi.org/10.1038/sj.bjc.6602061 CrossRefPubMedPubMedCentral

Le Jeune I, Gribbin J, West J et al (2007) The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med 101(12):2534–2540. https://doi.org/10.1016/j.rmed.2007.07.012 CrossRefPubMed

Sato T, Teramukai S, Kondo H et al (2014) Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg 147(5):1604–1611.e1603. https://doi.org/10.1016/j.jtcvs.2013.09.050 CrossRefPubMed

Omori T, Tajiri M, Baba T et al (2015) Pulmonary resection for lung cancer in patients with idiopathic interstitial pneumonia. Ann Thorac Surg 100(3):954–960. https://doi.org/10.1016/j.athoracsur.2015.03.094 CrossRefPubMed

Kenmotsu H, Naito T, Kimura M et al (2011) The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol 6(7):1242–1246. https://doi.org/10.1097/JTO.0b013e318216ee6b CrossRefPubMed

Kanai O, Kim YH, Demura Y et al (2018) Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. Thorac Cancer 9(7):847–855. https://doi.org/10.1111/1759-7714.12759 CrossRefPubMedPubMedCentral

Hanibuchi M, Kakiuchi S, Atagi S et al (2018) A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease. Lung Cancer 125:93–99. https://doi.org/10.1016/j.lungcan.2018.09.007 CrossRefPubMed

Kakiuchi S, Hanibuchi M, Tezuka T et al (2017) Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: a feasibility of S-1. Respir Investig 55(2):145–152. https://doi.org/10.1016/j.resinv.2016.10.008 CrossRefPubMed

Chen YJ, Chen LX, Han MX et al (2015) The efficacy and safety of chemotherapy in patients with nonsmall cell lung cancer and interstitial lung disease: a prisma-compliant bayesian meta-analysis and systematic review. Medicine (Baltimore) 94(36):e1451. https://doi.org/10.1097/MD.0000000000001451 CrossRef

10.

Ott PA, Bang YJ, Piha-Paul SA et al (2019) T-Cell-Inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol 37(4):318–327. https://doi.org/10.1200/jco.2018.78.2276 CrossRefPubMed

11.

Yamaguchi T, Shimizu J, Hasegawa T et al (2018) Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: a retrospective analysis. Lung Cancer 125:212–217. https://doi.org/10.1016/j.lungcan.2018.10.001 CrossRefPubMed

12.

Shibaki R, Murakami S, Matsumoto Y et al (2019) Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease. Medical Oncol (Northwood, Lond, Engl) 36(6):49. https://doi.org/10.1007/s12032-019-1274-0 CrossRef

13.

Fujimoto D, Morimoto T, Ito J et al (2017) A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia. Lung Cancer 111:1–5. https://doi.org/10.1016/j.lungcan.2017.06.008 CrossRefPubMed

14.

Raghu G, Remy-Jardin M, Myers JL et al (2018) Diagnosis of idiopathic pulmonary fibrosis. An Official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 198(5):e44–e68CrossRef

15.

Masuda T, Hirano C, Horimasu Y et al (2018) The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 81(1):131–139. https://doi.org/10.1007/s00280-017-3476-5 CrossRefPubMed

16.

Mirsadraee S, Oswal D, Alizadeh Y et al (2012) The 7th lung cancer TNM classification and staging system: review of the changes and implications. World J Radiol 4(4):128–134. https://doi.org/10.4329/wjr.v4.i4.128 CrossRefPubMedPubMedCentral

17.

Travis WD, Brambilla E, Nicholson AG et al (2015) The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10(9):1243–1260. https://doi.org/10.1097/jto.0000000000000630 CrossRef

18.

Enomoto Y, Inui N, Kato T et al (2016) Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer. Lung Cancer 96:63–67. https://doi.org/10.1016/j.lungcan.2016.03.017 CrossRefPubMed

19.

Kazerooni EA, Martinez FJ, Flint A et al (1997) Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 169(4):977–983. https://doi.org/10.2214/ajr.169.4.9308447 CrossRefPubMed

20.

Goddard PR, Nicholson EM, Laszlo G et al (1982) Computed tomography in pulmonary emphysema. Clin Radiol 33(4):379–387CrossRef

21.

Suzuki H, Sekine Y, Yoshida S et al (2011) Risk of acute exacerbation of interstitial pneumonia after pulmonary resection for lung cancer in patients with idiopathic pulmonary fibrosis based on preoperative high-resolution computed tomography. Surg Today 41(7):914–921. https://doi.org/10.1007/s00595-010-4384-z CrossRefPubMed

22.

Collard HR, Ryerson CJ, Corte TJ et al (2016) Acute exacerbation of idiopathic pulmonary fibrosis. An International Working Group Report. Am J Respir Crit Care Med 194(3):265–275. https://doi.org/10.1164/rccm.201604-0801C CrossRef

23.

Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48(3):452–458. https://doi.org/10.1038/bmt.2012.244 CrossRefPubMed

24.

Ryerson CJ, Vittinghoff E, Ley B et al (2014) Predicting survival across chronic interstitial lung disease: The ILD-GAP model. Chest 145(4):723–728. https://doi.org/10.1378/chest.13-1474 CrossRef

25.

Singh S, Collins BF, Sharma BB et al (2017) Interstitial lung disease in India. Results of a prospective registry. Am J Respir Crit Care Med 195(6):801–813. https://doi.org/10.1164/rccm.201607-1484OC CrossRef

26.

Usui Y, Kenmotsu H, Mori K et al (1438PA) 1438PA multicenter single-arm phase II study of nab-paclitaxel/carboplatin for non-small cell lung cancer patients with interstitial lung disease. Ann Oncol. https://doi.org/10.1093/annonc/mdy292.060 CrossRef

27.

Reck M, Rodriguez-Abreu D, Robinson AG et al (2019) Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 37(7):537–546. https://doi.org/10.1200/jco.18.00149 CrossRefPubMed

28.

Socinski MA, Bondarenko I, Karaseva NA et al (2012) Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 30(17):2055–2062. https://doi.org/10.1200/jco.2011.39.5848 CrossRefPubMed

29.

Kenmotsu H, Naito T, Mori K et al (2015) Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. Cancer Chemother Pharmacol 75(3):521–526. https://doi.org/10.1007/s00280-014-2670-y CrossRefPubMed

30.

Horn L, Spigel DR, Vokes EE et al (2017) Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol 35(35):3924–3933. https://doi.org/10.1200/jco.2017.74.3062 CrossRefPubMedPubMedCentral

31.

Fujimoto D, Sato Y, Morimoto T et al (2018) Programmed cell death ligand 1 expression in non-small-cell lung cancer patients with interstitial lung disease: a matched case-control study. Clin Lung Cancer. https://doi.org/10.1016/j.cllc.2018.04.012 CrossRefPubMed

32.

Rizvi NA, Hellmann MD, Snyder A et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York) 348(6230):124–128. https://doi.org/10.1126/science.aaa1348 CrossRefPubMedCentral

33.

Honda T, Sakashita H, Masai K et al (2018) Deleterious pulmonary surfactant system gene mutations in lung adenocarcinomas associated with usual interstitial pneumonia. JCO Precis Oncol 2:1–24. https://doi.org/10.1200/po.17.00301 CrossRef

34.

Isobe K, Kaburaki K, Kobayashi H et al (2018) New risk scoring system for predicting acute exacerbation of interstitial pneumonia after chemotherapy for lung cancer associated with interstitial pneumonia. Lung Cancer 125:253–257. https://doi.org/10.1016/j.lungcan.2018.10.008 CrossRefPubMed

35.

Isobe K, Hata Y, Sakamoto S et al (2010) Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anti-cancer therapy. Respirology (Carlton, Vic) 15(1):88–92. https://doi.org/10.1111/j.1440-1843.2009.01666.x CrossRef

36.

Nakao A, Hasegawa Y, Tsuchiya Y et al (1995) Expression of cell adhesion molecules in the lungs of patients with idiopathic pulmonary fibrosis. Chest 108(1):233–239. https://doi.org/10.1378/chest.108.1.233 CrossRefPubMed

37.

Strieter RM (2005) Pathogenesis and natural history of usual interstitial pneumonia: the whole story or the last chapter of a long novel. Chest 128(5 Suppl 1):526s–532s. https://doi.org/10.1378/chest.128.5_suppl_1.526S CrossRefPubMed

38.

Balestro E, Calabrese F, Turato G et al (2016) Immune inflammation and disease progression in idiopathic pulmonary fibrosis. PLoS One 11(5):e0154516. https://doi.org/10.1371/journal.pone.0154516 CrossRefPubMedPubMedCentral

39.

Parra ER, Kairalla RA, Ribeiro de Carvalho CR et al (2007) Inflammatory cell phenotyping of the pulmonary interstitium in idiopathic interstitial pneumonia. Respiration 74(2):159–169. https://doi.org/10.1159/000097133 CrossRefPubMed

40.

Leuschner G, Behr J (2017) Acute exacerbation in interstitial lung disease. Frontiers in medicine 4:176. https://doi.org/10.3389/fmed.2017.00176 CrossRefPubMedPubMedCentral

41.

Vuga LJ, Tedrow JR, Pandit KV et al (2014) C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 189(8):966–974. https://doi.org/10.1164/rccm.201309-1592OC CrossRefPubMedPubMedCentral

42.

Cocconcelli E, Balestro E, Biondini D et al (2019) High-resolution computed tomography (hrct) reflects disease progression in patients with idiopathic pulmonary fibrosis (IPF): relationship with lung pathology. J Clin Med. https://doi.org/10.3390/jcm8030399 CrossRefPubMedPubMedCentral

43.

Kim TS, Lee KS, Chung MP et al (1998) Nonspecific interstitial pneumonia with fibrosis: high-resolution CT and pathologic findings. AJR Am J Roentgenol 171(6):1645–1650. https://doi.org/10.2214/ajr.171.6.9843306 CrossRefPubMed

Titel: The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease
verfasst von: Naoki Nishiyama
Takayuki Honda
Manabu Sema
Tatsuo Kawahara
Yasuto Jin
Ichiro Natsume
Tomoshige Chiaki
Takaaki Yamashita
Yoshikazu Tsukada
Reiko Taki
Yoshihiro Miyashita
Kazuhito Saito
Tomoya Tateishi
Hiroyuki Sakashita
Yasunari Miyazaki
Publikationsdatum: 13.11.2019
Verlag: Springer Singapore
Erschienen in: International Journal of Clinical Oncology / Ausgabe 2/2020
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-019-01576-x

Springer Medizin

The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease